238 related articles for article (PubMed ID: 15611294)
1. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia.
Yasuda T; Shirakata M; Iwama A; Ishii A; Ebihara Y; Osawa M; Honda K; Shinohara H; Sudo K; Tsuji K; Nakauchi H; Iwakura Y; Hirai H; Oda H; Yamamoto T; Yamanashi Y
J Exp Med; 2004 Dec; 200(12):1681-7. PubMed ID: 15611294
[TBL] [Abstract][Full Text] [Related]
2. Role of Dok-1 and Dok-2 in leukemia suppression.
Niki M; Di Cristofano A; Zhao M; Honda H; Hirai H; Van Aelst L; Cordon-Cardo C; Pandolfi PP
J Exp Med; 2004 Dec; 200(12):1689-95. PubMed ID: 15611295
[TBL] [Abstract][Full Text] [Related]
3. Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling.
Shinohara H; Inoue A; Toyama-Sorimachi N; Nagai Y; Yasuda T; Suzuki H; Horai R; Iwakura Y; Yamamoto T; Karasuyama H; Miyake K; Yamanashi Y
J Exp Med; 2005 Feb; 201(3):333-9. PubMed ID: 15699069
[TBL] [Abstract][Full Text] [Related]
4. Dok-1 and Dok-2 are negative regulators of T cell receptor signaling.
Yasuda T; Bundo K; Hino A; Honda K; Inoue A; Shirakata M; Osawa M; Tamura T; Nariuchi H; Oda H; Yamamoto T; Yamanashi Y
Int Immunol; 2007 Apr; 19(4):487-95. PubMed ID: 17329234
[TBL] [Abstract][Full Text] [Related]
5. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
6. Dok-1 tyrosine residues at 336 and 340 are essential for the negative regulation of Ras-Erk signalling, but dispensable for rasGAP-binding.
Shinohara H; Yasuda T; Yamanashi Y
Genes Cells; 2004 Jun; 9(6):601-7. PubMed ID: 15189452
[TBL] [Abstract][Full Text] [Related]
7. Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase.
Uchida M; Enomoto A; Fukuda T; Kurokawa K; Maeda K; Kodama Y; Asai N; Hasegawa T; Shimono Y; Jijiwa M; Ichihara M; Murakumo Y; Takahashi M
J Cell Sci; 2006 Aug; 119(Pt 15):3067-77. PubMed ID: 16820412
[TBL] [Abstract][Full Text] [Related]
8. Crk-associated substrate lymphocyte type regulates myeloid cell motility and suppresses the progression of leukemia induced by p210Bcr/Abl.
Seo S; Nakamoto T; Takeshita M; Lu J; Sato T; Suzuki T; Kamikubo Y; Ichikawa M; Noda M; Ogawa S; Honda H; Oda H; Kurokawa M
Cancer Sci; 2011 Dec; 102(12):2109-17. PubMed ID: 21848808
[TBL] [Abstract][Full Text] [Related]
9. Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase.
Gérard A; Favre C; Garçon F; Némorin JG; Duplay P; Pastor S; Collette Y; Olive D; Nunès JA
Oncogene; 2004 Feb; 23(8):1594-8. PubMed ID: 14647425
[TBL] [Abstract][Full Text] [Related]
10. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
[TBL] [Abstract][Full Text] [Related]
11. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
12. Model mice for BCR/ABL-positive leukemias.
Honda H; Hirai H
Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
14. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
[TBL] [Abstract][Full Text] [Related]
15. Dok-1 is a positive regulator of IL-4 signalling and IgE response.
Inoue A; Yasuda T; Yamamoto T; Yamanashi Y
J Biochem; 2007 Aug; 142(2):257-63. PubMed ID: 17827176
[TBL] [Abstract][Full Text] [Related]
16. The roles of Dok family adapters in immunoreceptor signaling.
Mashima R; Hishida Y; Tezuka T; Yamanashi Y
Immunol Rev; 2009 Nov; 232(1):273-85. PubMed ID: 19909370
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphorylation of p62(Dok) induced by cell adhesion and insulin: possible role in cell migration.
Noguchi T; Matozaki T; Inagaki K; Tsuda M; Fukunaga K; Kitamura Y; Kitamura T; Shii K; Yamanashi Y; Kasuga M
EMBO J; 1999 Apr; 18(7):1748-60. PubMed ID: 10202139
[TBL] [Abstract][Full Text] [Related]
18. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
19. p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
Brusa G; Benvenuti M; Mazzacurati L; Mancini M; Pattacini L; Martinelli G; Barbieri E; Greenberger JS; Baccarani M; Santucci MA
Haematologica; 2003 Jun; 88(6):622-30. PubMed ID: 12801837
[TBL] [Abstract][Full Text] [Related]
20. p62(dok), a negative regulator of Ras and mitogen-activated protein kinase (MAPK) activity, opposes leukemogenesis by p210(bcr-abl).
Di Cristofano A; Niki M; Zhao M; Karnell FG; Clarkson B; Pear WS; Van Aelst L; Pandolfi PP
J Exp Med; 2001 Aug; 194(3):275-84. PubMed ID: 11489947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
